- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Antihistamine, selectively blocks H1-histamine receptors. Reduces the severity of histamine-mediated allergic reactions.
Quickly eliminates the symptoms of allergic rhinitis (sneezing, itching in the nasal cavity, rhinorrhea) and improves nasal breathing (by reducing the swelling of the nasal mucosa).
No carcinogenic and mutagenic effects, and no effect on fertility. In doses exceeding the recommended for humans in 2500 times, has teratogenic activity (increases the frequency of embryo resorption).
Allergic rhinitis, pollinosis.
Levocabastine hydrochloride 540 mcg, which corresponds. Levocabastine 500 mcg
Excipients: propylene glycol - 48.26 μl, sodium hydrogen phosphate - 8.66 mg, sodium hydrogen phosphate monohydrate - 5.38 mg, hypromellose (2910 5 mPa.s) - 2.5 mg, polysorbate 80 - 1 mg, benzalkonium chloride - 150 μg (as a 50% solution - 30 mcl), disodium edetate - 150 mcg, water for injection - up to 1 ml.
Levocabastine is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Tyzine allergy||Janssen Pharmaceuticals N.V||Belgium||spray|
|Visine allergy||Johnson and johnson||USA||eye drops|
No customer reviews for the moment.
Dosage and Administration
Intranasally administered to adults and children over 6 years old, 2 doses (100 μg) in each nasal passage 2 times / day. Use of the drug should be continued until symptoms are eliminated. With more pronounced symptoms of the drug Tyzine allergy can be used 3-4 times / day.
The patient should be warned about the need to clear the nasal cavity before using the spray and inhale through the nose during the injection.
Before first use, remove the protective cap and repeatedly press the spray nozzle until a cloud of "fog" appears. The bottle is ready for further use. Drug inhale through the nose.
Shake the bottle before each use.
Adverse events reported in ≥1% of patients during clinical trials
On the part of the digestive system: nausea.
From the nervous system: headache, drowsiness, dizziness.
On the part of the respiratory system: pain in the pharynx and larynx, nosebleeds, cough.
Other: fatigue, pain at the injection site.
Adverse reactions that were noted in the Co side of the respiratory system: short-term local irritation, pain at the injection site, dryness, burning sensation, discomfort in the nasal cavity.
Determination of the frequency of adverse reactions: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (> 1/10 000, <1 1000="" very="" rarely="" 1="" 10="" 000="" including="" individual="" cases="" br="">Since the cardiovascular system: rarely - tachycardia.
On the part of the immune system: rarely - allergic reactions.
On the part of the respiratory system: rarely - swelling of the nasal mucosa; infrequently - shortness of breath; frequency is unknown - bronchospasm.
Other: infrequently - malaise; frequency is unknown - swelling of the eyelids.
- children's age up to 6 years;
- Hypersensitivity to the components of the drug Tyzine allergy.
Precautions should be prescribed the drug to patients with impaired renal function and elderly patients.
Pregnancy and Lactation
Reliable data on the use of nasal spray Tizin® Alergi in pregnant women are not available. Therefore, the drug should not be used during pregnancy unless the intended benefit to the mother justifies the potential risk to the fetus.
Based on the determination of the concentration of levocabastin in the saliva and breast milk of lactating women who once received 0.5 mg of levocabastin by mouth, it is expected that approximately 0.6% of the total intranasal dose of levocabastin can be administered to the infant during breastfeeding. If necessary, the appointment of the drug during lactation should stop breastfeeding.
Influence on ability to drive motor transport and control mechanisms
The drug Tizin Alerji in the recommended dose usually does not have a clinically pronounced sedative effect and does not reduce the speed of the reaction compared with placebo. In the case of drowsiness in the use of the drug should not engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
The patient should be informed that if the drug has become unusable or the expiration date has expired, then it should not be thrown into the wastewater or on the street. It is necessary to put the drug in the bag and put it in the trash. These measures will help protect the environment.
No reports of overdose of levocabastin have been reported.
Symptoms: in case of accidental ingestion, a decrease in blood pressure, tachycardia, a slight sedation is possible.
Treatment: if ingested, the patient should drink a large amount of fluid to speed up the release of levocabastine by the kidneys.
- Brand name: Tyzine allergy
- Active ingredient: Levocabastine
- Dosage form: Spray nasal dosed.
- Manufacturer: Janssen Pharmaceuticals N.V.
- Country of Origin: Belgium
Studies and clinical trials of Levocabastine (Click to expand)
- Levocabastine (R 50547): The prototype of a chemical series of compounds with specific H1-antihistaminic activity
- A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis
- Safety and Efficacy Comparison of Emedastine 0.05% Ophthalmic Solution Compared to Levocabastine 0.05% Ophthalmic Suspension in Pediatric Subjects with Allergic Conjunctivitis
- An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic Conjunctivitis
- Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics
- Efficacy of levocabastine in conjunctival provocation studies
- Levocabastine eye drops in the treatment of vernal conjunctivitis
- Tolerability of levocabastine eye drops
- Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions
- Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis
- The effect of levocabastine and furosemide pretreatment on hyperreactive response after nasal provocation with hypotonic aerosol in subjects with allergic rhinitis
- Nedocromil sodium and levocabastine
- Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis
- Levocabastine eye drops versus sodium cromoglycate in seasonal allergic conjunctivitis
- Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis
- A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis
- Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis
- Topical levocabastine an effective alternative to oral antihistamines in seasonal allergic rhinoconjunctivitis
- Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro
- A Double-Blind Evaluation of Topical Levocabastine, a New Specific H1 Antagonist in Patients with Allergic Conjunctivitis
- Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis
- Effect of topical levocabastine on allergic and non-allergic perennial rhinitis : A double-blind study, levocabastine vs. placebo, followed by an open, prospective, single-blind study on beclomethasone
- Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis
- Absence of central effects with levocabastine eye drops